Physician profile
Brian David Feiock
NPI 1841272549
$4,497.96
in general payments reported to CMS, 2019-2025
21 companies · $549 in 2025
The $549 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $456 · 2020: $430 · 2021: $985 · 2022: $935 · 2023: $491 · 2024: $651 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,691.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,560.25 | 2019-2025 | |
| Janssen Biotech, INC. | $623.58 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $345.05 | 2019-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $231.89 | 2019-2025 | Entyvio |
| Celgene Corporation | $201.75 | 2021-2024 | Zeposia |
| Genzyme Corporation | $109.04 | 2022-2025 | |
| Madrigal Pharmaceuticals | $55.21 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $45.73 | 2022-2023 | Dupixent |
| Gilead Sciences, INC. | $40.76 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $38.24 | 2024 | Dificid |
| Intuitive Surgical, INC. | $35.70 | 2019 | |
| Lucid Diagnostics INC. | $29.64 | 2023 | |
| Tersera Therapeutics LLC | $28.27 | 2021 | |
| Redhill Biopharma INC. | $24.80 | 2021 | |
| Fresenius Kabi USA, LLC | $23.34 | 2023 | Idacio |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $20.83 | 2019 | |
| Biocon Biologics INC | $20.52 | 2024 | Hulio |
| Qol Medical, LLC | $19.23 | 2023 | Sucraid |
| Ardelyx, INC. | $15.27 | 2023 | Ibsrela |
| Boston Scientific Corporation | $14.64 | 2022 | |
| Daiichi Sankyo INC. | $14.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Feiock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.